Illumina, Inc. $ILMN Shares Purchased by California Public Employees Retirement System

California Public Employees Retirement System grew its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 1.1% in the 1st quarter, Holdings Channel.com reports. The institutional investor owned 334,139 shares of the life sciences company’s stock after purchasing an additional 3,477 shares during the period. California Public Employees Retirement System’s holdings in Illumina were worth $41,186,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in ILMN. Nordea Investment Management AB raised its holdings in shares of Illumina by 2,792.2% during the 4th quarter. Nordea Investment Management AB now owns 944,500 shares of the life sciences company’s stock valued at $124,145,000 after purchasing an additional 911,843 shares in the last quarter. Impact Partnership Wealth LLC lifted its stake in shares of Illumina by 235.8% in the 1st quarter. Impact Partnership Wealth LLC now owns 11,080 shares of the life sciences company’s stock valued at $1,366,000 after purchasing an additional 7,780 shares during the last quarter. SG Americas Securities LLC boosted its holdings in Illumina by 8.0% in the first quarter. SG Americas Securities LLC now owns 86,318 shares of the life sciences company’s stock worth $10,640,000 after purchasing an additional 6,425 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al boosted its holdings in Illumina by 27.4% in the fourth quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 348,011 shares of the life sciences company’s stock worth $45,645,000 after purchasing an additional 74,900 shares in the last quarter. Finally, Louisiana State Employees Retirement System acquired a new position in Illumina during the first quarter worth $5,460,000. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Insiders Place Their Bets

In related news, Director Keith A. Meister sold 235,000 shares of the stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $163.63, for a total transaction of $38,453,050.00. Following the completion of the sale, the director owned 2,830,452 shares in the company, valued at $463,146,860.76. This represents a 7.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Scott M. Davies sold 615 shares of the firm’s stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $180.00, for a total value of $110,700.00. Following the completion of the sale, the insider directly owned 20,953 shares in the company, valued at $3,771,540. This trade represents a 2.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 1,003,769 shares of company stock worth $155,710,908 in the last 90 days. 2.90% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several research firms have weighed in on ILMN. Guggenheim raised their target price on Illumina from $180.00 to $200.00 and gave the company a “buy” rating in a report on Monday, June 29th. Leerink Partners increased their price objective on Illumina from $175.00 to $210.00 and gave the company an “outperform” rating in a report on Friday. Wall Street Zen downgraded Illumina from a “buy” rating to a “hold” rating in a research note on Saturday. Citigroup boosted their target price on Illumina from $80.00 to $95.00 and gave the stock a “sell” rating in a report on Monday, May 4th. Finally, Royal Bank Of Canada began coverage on Illumina in a research report on Thursday, May 14th. They set an “outperform” rating and a $170.00 target price for the company. Nine equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $156.88.

Illumina Stock Down 1.1%

Illumina stock opened at $184.68 on Tuesday. The firm has a market cap of $27.94 billion, a price-to-earnings ratio of 33.58, a P/E/G ratio of 3.49 and a beta of 1.47. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.75 and a quick ratio of 1.36. Illumina, Inc. has a fifty-two week low of $88.00 and a fifty-two week high of $196.66. The firm has a fifty day moving average price of $167.28 and a two-hundred day moving average price of $143.77.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.05 by $0.10. The company had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.07 billion. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The firm’s revenue was up 4.8% compared to the same quarter last year. During the same period last year, the business posted $0.97 earnings per share. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, analysts forecast that Illumina, Inc. will post 5.22 earnings per share for the current year.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.